IL6 and cancer: In a phase II open, non-randomized trial, a cumulative EPI dose of 200 mg/m2 among cancer patients was found to induce impairment in systolic left ventricular (LV) function characterized by a reduction in the strain rate (SR) peak at 3, 6, 12, and 18 months of follow-up that correlated with the expression of inflammatory interleukin-6 (IL-6) and oxidative stress markers [61].